Table 2.
Recorded clinical values before starting drugs or at study entry for prevalent users
| Clinical variables | Glitazones | Gliptins | Metformin | Sulphonylureas | Insulin | Other diabetes drugs |
|---|---|---|---|---|---|---|
| Total No of patients exposed | 21 308 | 32 533 | 256 024 | 134 570 | 19 791 | 12 062 |
| Variables recorded (%): | ||||||
| Haemoglobin A1c | 21 251 (99.7) | 32 474 (99.8) | 253 219 (98.9) | 133 170 (99.0) | 19 255 (97.3) | 12 022 (99.7) |
| Body mass index | 21 120 (99.1) | 32 224 (99.1) | 252 290 (98.5) | 132 477 (98.4) | 19 436 (98.2) | 11 749 (97.4) |
| Cholesterol to HDL ratio | 18 264 (85.7) | 29 307 (90.1) | 224 504 (87.7) | 115 991 (86.2) | 16 723 (84.5) | 10 619 (88.0) |
| Systolic blood pressure | 21 306 (100.0) | 32 529 (100.0) | 255 892 (99.9) | 134 487 (99.9) | 19 765 (99.9) | 12 057 (100.0) |
| Creatinine level | 21 288 (99.9) | 32 509 (99.9) | 255 381 (99.7) | 134 244 (99.8) | 19 655 (99.3) | 12 044 (99.9) |
| Total recorded | 18 097 (84.9) | 29 010 (89.2) | 220 119 (86.0) | 113 843 (84.6) | 16 270 (82.2) | 10 340 (85.7) |
| Mean (SD) values: | ||||||
| Haemoglobin A1c (mmol/mol) | 66.8 (18.9) | 68.4 (18.4) | 61.4 (18.7) | 64.9 (19.9) | 75.4 (22.7) | 70.9 (19.6) |
| Body mass index (kg/m2) | 31.7 (6.0) | 31.7 (5.9) | 30.6 (5.9) | 30.1 (5.8) | 30.2 (6.1) | 34.1 (6.6) |
| Cholesterol to HDL ratio | 3.8 (1.3) | 3.9 (1.3) | 3.8 (1.3) | 3.8 (1.3) | 4.0 (1.4) | 4.0 (1.3) |
| Systolic blood pressure (mm Hg) | 133.1 (14.8) | 132.3 (14.7) | 132.5 (15.3) | 132.8 (15.9) | 131.7 (16.9) | 132.5 (14.9) |
| Creatinine level | 87.1 (33.7) | 84.9 (33.3) | 84.8 (30.1) | 92.1 (47.7) | 99.3 (62.0) | 83.5 (34.6) |
HDL=high density lipoprotein cholesterol.
Values represent those recorded before starting drugs or at study entry for prevalent users. Treatment groups not mutually exclusive.